BRCA1-deficient cells show defects in DNA repair and rely on other members of the DNA repair machinery, which makes them sensitive to PARP inhibitors (PARPi). Although carrying a germline pathogenic variant in BRCA1/2 is the best determinant of response to PARPi, a significant percentage of the patients do not show sensitivity and/or display increased toxicity to the agent. Considering previously suggested mutation-specific BRCA1 haploinsufficiency, we aimed to investigate whether there are any differences in cellular response to PARPi olaparib depending on the BRCA1 mutation type. Lymphoblastoid cell lines derived from carriers of missense pathogenic variants in the BRCA1 BRCT domain (c.5117G > A, p.Gly1706Glu and c.5123C > A, p.Ala1708Glu) showed higher sensitivity to olaparib than cells with truncating variants or wild types (WT). Response to olaparib depended on a basal PARP enzymatic activity, but did not correlate with PARP1 expression. Interestingly, cellular sensitivity to the agent was associated with the level of BRCA1 recruitment into cH2AX foci, being the lowest in cells with missense variants. Since these variants lead to partially stable protein mutants, we propose a model in which the mutant protein acts in a dominant negative manner on the WT BRCA1, impairing the recruitment of BRCA1 into DNA damage sites and, consequently, increasing cellular sensitivity to PARPi. Taken together, our results indicate that carriers of different BRCA1 mutations could benefit from olaparib in a distinct way and show different toxicities to the agent, which could be especially relevant for a potential future use of PARPi as prophylactic agents in BRCA1 mutation carriers.
Introduction
Carrying a germline pathogenic variant in the BRCA1 gene predisposes individuals to breast, ovarian and other cancers (1) . Since BRCA1 is an important player in the DNA repair pathway, BRCA1-deficient cells need to rely on other members of the DNA repair machinery, which makes them sensitive to drugs which target those repair pathways (e.g. PARP inhibitors, PARPi). PARP enzymes are involved in a DNA single-strand break (SSB) repair pathway (2) and if inhibited, naturally occurring SSBs cannot be repaired, leading to a formation of double-strand breaks (DSBs) and replication forks collapse. Unrepaired DSBs in BRCA-deficient cells then result in cell death (3) . Such synthetic lethal interaction between BRCA1/2 and PARP1 was first described by Farmer et al. and became a promising therapeutic strategy for breast, ovarian and other cancers (4, 5) .
PARPi olaparib, evaluated for its safety and tolerability in multiple studies, shows a significant clinical activity in patients carrying germline pathogenic variants in BRCA1 or BRCA2 genes (6) (7) (8) (9) . Based on its encouraging results, in December 2014, olaparib received a marketing authorization by the European Commission for the maintenance treatment of platinumsensitive BRCA-deficient high grade serous ovarian carcinoma and by the FDA (The U.S. Food and Drug Administration) for the treatment of recurrent ovarian cancer in BRCA1/2-mutated women (10) .
However, although carrying a germline pathogenic variant in BRCA1/2 is the best determinant of response to olaparib, a considerable percentage of these patients do not show sensitivity to the treatment or display increased toxicity to the agent. A multicentre phase II trial revealed an objective response rate of 41% in patients with germline BRCA1/2-deficient advanced breast cancer after treatment with 400mg olaparib twice daily (8) , and the response rate varied between 13-41% using olaparib as a single agent in recurrent ovarian cancer (11) (12) (13) . Regarding toxicity, although olaparib is generally well tolerated, grade !3 adverse events are not rare (7) and data about long-term toxicity is not available yet. Thus, further investigation is clearly necessary for the best utilization of this potent compound in the clinics.
Taking into account the inter-individual variability in the disease manifestation among carriers of BRCA1 pathogenic variants, partially explained by the location and type of mutations in BRCA1 (14) , the objective of this work was to investigate whether there are any differences in the cellular response to olaparib, depending on the BRCA1 mutation type. In the present study, we describe for the first time that lymphoblastoid cell lines (LCLs), derived from carriers of pathogenic missense mutations in the BRCA1 BRCT domain (namely c.5117G > A, p.Gly1706Glu and c.5123C > A, p.Ala1708Glu), show a higher sensitivity to olaparib than cells with truncating mutations or wild type (WT). These results indicate that carriers of different BRCA1 pathogenic variants could benefit from the treatment in a distinct way and that they could display different toxicities. Moreover, we propose and validate a mechanism by which the cells harbouring heterozygous missense pathogenic variants in BRCA1 show increased sensitivity to olaparib.
Results

Cells harbouring heterozygous missense pathogenic variants in the BRCA1 BRCT domain are more sensitive to olaparib than WT cells or cells with truncating variants
In order to investigate the sensitivity of BRCA1 heterozygous mutation carrier cells to olaparib we used a previously characterized panel of 21 LCLs (15) . Viability assay revealed that LCLs derived from carriers of BRCA1 truncating variants showed comparable sensitivity levels to various concentrations of olaparib as WT cells (Fig. 1A and B) . Average values and standard deviations from three independent experiments are listed in Supplementary Material, Table S1 . On the other hand, cells harbouring missense pathogenic variants in the BRCA1 BRCT domains were significantly more sensitive to 8lM olaparib than both WTs and cells with truncating mutations.
The cellular growth rate (GR) did not vary between groups of LCLs depending on their BRCA1 mutation status, however, the GR and viability of cells after treatment with olaparib were significantly negatively correlated (Supplementary Material, Fig.  S1 ). Because of this relationship, GR was taken into account as a cofounding factor while performing the statistical analysis of cellular response to olaparib (P-value in Fig. 1B) . Nevertheless, the differences in response of mutated cells to olaparib remained significant, indicating a GR-independent variability in cellular sensitivity to this agent.
Transcriptional activation function of the BRCA1 BRCT domains does not seem to be involved in modulation of cellular sensitivity to olaparib Predicted co-occurrence of mutant and WT BRCA1 protein in cells carrying heterozygous missense variants, previously studied in our lab (15) , brings the possibility of a dominant-negative effect of the mutant. We used a well-described cell-based transcriptional assay (16, 17) to measure the ability of BRCA1 C-terminal region to activate transcription of a reporter gene, a function dependent on the BRCT domains where both missense variants from our panel are located. Transcriptional activity of constructs containing WT BRCA1 (positive control) and missense variants M1775R (negative control), G1706E and A1708E, and a combination of WT þ A1708E in a HEK293FT cellular model ( Fig. 2A and B) was analysed. Co-transfection of WT and A1708E constructs mimicked the heterozygous status present in our LCLs and allowed us to test a possible negative effect of the mutated variant on WT protein function.
Western blot analysis confirmed an overexpression of all transfected BRCA1 constructs in both DMSO-and olaparibtreated HEK293FT cells (Fig. 2C) . As expected, WT BRCA1 was able to activate transcription of the reporter gene (Fig. 2D) whereas the negative control and both tested missense variants (G1706E, A1708E) displayed an altered ability to transcribe the luciferase gene. On the other hand, co-transfection of constructs containing WT and A1708E variants led to a transcriptional activation, which was comparable to the one induced by WT construct alone, indicating that the A1708E variant does not act in a dominant-negative manner to a WT BRCA1 transcriptional activation function. Olaparib slightly decreased the ability of WT BRCA1 to activate transcription of the reporter gene (82% of the WT), however the decrease did not reach the threshold of 50% to be considered of functional impact.
Olaparib induces changes in BRCA1 BRCT protein interactors and phosphorylation of threonine residue at position 1834
To further investigate whether olaparib treatment influences functions mediated by the BRCA1 BRCT domains, we analysed BRCT-mediated protein interactions and examined whether they are modulated by PARP inhibition. For this purpose, we used HEK293FT cells overexpressing the BRCA1 BRCT domains, which was either WT or carrying the G1706E variant, and treated them either with DMSO (control) or olaparib (16lM). We then analysed BRCT-bound protein complexes by tandem affinity purification coupled with mass spectrometry (TAP-MS) (detailed protocol in the Materials and Methods section).
We were unable to overexpress the mutated BRCT at levels sufficient for further mass spectrometry analysis (Supplementary Material, Fig. S2A ). However, even the effect of olaparib treatment on the WT BRCT protein interactions provided a valuable insight into the mechanism of olaparib action. After applying the SAINT (Significance Analysis of INTeractome) algorithm (18) to our data and setting a probability threshold of 0.8 À 1, we ended up with a list of 121 protein interactors (Supplementary Material, Fig. S2A ) (full list shown in Supplementary Material, Table S2 ). Most of the proteins (108/ 121 ¼ 89%) were found to interact with BRCT in both control and olaparib-treated cells. However, 11 interactors were found to be olaparib treatment-specific (Table 1) .
To get further insights into the functional roles of proteins interacting with the BRCA1 BRCT domain, we performed an enrichment analysis of the set of 121 proteins by using Ingenuity Pathway Analysis (IPA), taking into account the value of foldchange spectral counts. As expected, among the top canonical pathways related to this set of proteins was "Role of BRCA1 in DNA Damage Response", which was found to be downregulated in olaparib-treated cells (as indicated by the negative z-score value of -1.6) and which indicates an alteration of this pathway by the treatment (Supplementary Materials, Fig. S3A , Table S3 ). The interactors were also found to be significantly involved in several molecular and cellular functions, such as "DNA Replication, Recombination, and Repair" (Supplementary Material, Fig. S3B ), and they were connected into a highly scored network within members of this function (score 61) (Supplementary Material, Fig. S3C ).
In addition, we detected a new BRCA1 phosphorylation site at position T1834 (located at the end of the C-terminal BRCT domain) in the olaparib-treated cells. According to the PhosphoSitePlus database (www.phosphosite.org) there are 109 BRCA1 phosphorylation sites reported up to date and they are implicated in various cellular processes (Supplementary Material, Fig. S4 ). However, the phosphorylation site at threonine 1834 has not been previously reported and could be therefore connected to an olaparib-specific response. According to the GPS 3.0 kinase prediction software (19) , MLK3 is the most likely regulatory kinase responsible for olaparib-induced BRCA1 T1834 phosphorylation (Supplementary Material, Table S4 ).
PARP1 enzymatic activity positively correlates with sensitivity of cells to olaparib
In order to explain the mutation type-dependent differences in the response of cells to olaparib we investigated factors that could potentially influence sensitivity to this treatment, including PARP1 gene and protein expression and its enzymatic activity. PARP1 mRNA expression was significantly decreased in cells harbouring truncating variants in BRCA1 compared to WT controls ( Fig. 3A ; P ¼ 0.028), the same cell lines which showed significantly lower expression of BRCA1 (15). However, although PARP1 mRNA and protein expression were significantly positively correlated ( Fig. 3C ; P ¼ 0.027), differences in PARP1 protein levels between WT and truncating groups failed to reach statistical significance (Fig. 3B-D) . Cells with missense and truncating Since it has been previously demonstrated that PARP1 expression and protein level only partially correlate with its enzymatic activity (20, 21) we checked the activity in LCLs using two distinct methods. Measuring poly ADP-ribose (PAR) levels by Western blot did not reveal any statistically significant differences between groups of cells (Fig. 4A) . In order to measure the enzymatic activity more precisely, we used a modified in vitro PARP activity assay that allowed us to determine basal PARP activity in cell lysates (i.e. non-induced naturally activated PARP present in LCLs). There were no statistically significant differences between groups of LCLs depending on their BRCA1 mutation status (Fig. 4B ). Nevertheless, results from both experiments indicate that cells harbouring missense pathogenic variants show slightly elevated PARP activity than cells with truncating mutation (Fig. 4A and B) , which could make them less tolerant to PARPi. Indeed, a trend for increased PARP activity in the missense variants correlated with increased sensitivity to olaparib (Fig. 4C ) although a causal relationship cannot be demonstrated.
No association between the sensitivity of cells to olaparib and BRCA1 or PARP1 gene expression was found (P values 0.660 and 0.653, respectively, for treatment with 8lM olaparib), indicating that expression levels of these two proteins do not play a role in regulation of the response to this agent.
BRCA1 recruitment into cH2AX foci is lower in cells with missense mutation in the BRCT domain than in cells with truncating mutation
A recent report from Li et al describes a biphasic recruitment of the BRCA1 tumour suppressor into DNA damage sites (22) . The early recruitment is dependent on PAR recognition by the BRCA1-BARD1 protein complex whereas the later phase requires functional BRCA1 BRCT domains. Thus, using PARP inhibitors in cells with altered BRCT domain would lead to an alteration of both BRCA1 recruitment phases, reassessing the hypothesis of a dominant-negative effect. High-throughput confocal microscopy was used to evaluate BRCA1 recruitment into DNA damage sites (measured by the intensity of the BRCA1 signal within cH2AX foci) in twelve DMSO-treated (control) or olaparib-treated LCLs.
Already under control conditions, BRCA1 signal intensity in cH2AX foci significantly varied among groups of LCLs, being the highest in WTs, lower in TRUN and the lowest in cells with a missense mutation in the BRCA1 BRCT domain (P value < 0.001 in all comparisons) (Fig. 5A ). As expected, olaparib treatment significantly increased nuclear cH2AX levels (Supplementary Material, Fig. S5 ; P value < 0.001 in all comparisons), which was accompanied by elevated BRCA1 recruitment in all groups of cells (Fig. 5A) . However, the cells with BRCT missense mutations again showed the lowest BRCA1 signal within cH2AX foci from all groups. Importantly, BRCA1 recruitment in both DMSO-and olaparib-treated cells was strongly positively correlated with cellular viability after treatment with olaparib ( Fig. 5B ), suggesting a possible causal relationship. The recruitment of the protein was not associated with total BRCA1 levels (r ¼ 0.121; P ¼ 0.709), indicating that the presence of a functional BRCA1 protein in DNA damage sites, and not the overall BRCA1 protein expression, influences the sensitivity of cells to olaparib.
Discussion
Olaparib is the first PARP inhibitor being approved by the European Commission as a maintenance treatment for platinum-sensitive relapsed BRCA-mutated high-grade serous epithelial ovarian cancer and by the FDA for treatment of recurrent ovarian cancer in BRCA-mutated women (10). However, not all patients that are carriers of BRCA pathogenic variants respond to the drug and a substantial fraction of them displays resistance and adverse reactions following the treatment (9,10), indicating the need to further investigate the best use of these compounds in the clinics (23) . There is increasing evidence that heterozygous pathogenic variants in the BRCA1 gene lead to haploinsufficiency for some of the multiple BRCA1 functions, including homologous recombination, repair of stalled replication forks and maintenance of genome integrity (15, (24) (25) (26) . The diversity of BRCA1 functions indicates that different pathogenic BRCA1 alleles may lead to distinct phenotypic effects in mutation carriers. Thus, we aimed to investigate whether carrying various heterozygous pathogenic variants in the BRCA1 gene increases cellular sensitivity to olaparib and whether and how BRCA1 mutation types influence such sensitivity.
Strikingly, while the treatment led to a comparable sensitivity of cells harbouring heterozygous truncating mutations as in WT cells, cell lines carrying the two studied missense variants (c.5117G > A and c.5123C > A) were the most sensitive group. Previous studies failed to observe increased sensitivity of BRCA1-heterozygous cells to olaparib unless they were pretreated with either ionization irradiation or UV (24, 27) . However, these reports were focussed on truncating mutations while we are, for the first time, analysing carriers of recurrent missense pathogenic variants in the BRCA1 BRCT domains. A recent study suggests that response to PARP inhibitor depends on the type of FANCD1/BRCA2 mutation, supporting our results and indicating that different mutations in DNA repair genes lead to variable phenotypes (28) . Our results indicate that treatment with olaparib could lead to an increased toxicity to the drug in individuals carrying c.5117G > A or c.5123C > A missense variants. Importantly, the olaparib concentration range used in our experiments was comparable to the peak plasma levels found in patients treated with this agent in clinical trials. It will be crucial to further validate our findings in available clinical data and check the level of toxicity and treatment outcomes in the variant carriers.
In our attempt to explain why cells harbouring c.5117G > A and c.5123C > A pathogenic variants in the BRCA1 BRCT domains are more sensitive to olaparib we explored the idea of a dominant-negative effect. Taking into account the expected presence of mutated protein in cells carrying missense mutation and the absence of truncated protein in cells carrying most of the truncating variants (15) , there is a possibility that the missense variants compete with the WT protein for certain functions. Since the BRCA1 BRCT domains are known to be involved in the transcriptional activation of target genes (29) we used a well characterised transcriptional activation assay (30) (31) (32) to test if the increased sensitivity of cells with the studied missense mutation to olaparib is caused by a dominantnegative effect on the BRCT-mediated transcriptional activation function.
Mimicking the heterozygous status present in mutated LCLs by simultaneous co-expression of WT and A1708E missense variant led to a comparable phenotype as over-expression of WT alone. These findings suggest that A1708E does not influence the WT transcriptional activation function, at least in our experimental design when using a fragment of the BRCA1 protein. Thus, a dominant-negative effect in the transcriptional activation function of the BRCA1 BRCT domain does not seem to be involved in the differences in response of cells to olaparib.
The high number of BRCT protein interactors allows BRCA1 to play a role in so complex cellular processes like cell cycle checkpoint regulation and maintenance of genomic stability (33) . Thus, in order to further puzzle out whether and how olaparib treatment affects functions mediated by the BRCA1 BRCT domain, we looked at the BRCA1 BRCT protein interactors in olaparib-treated cells. We identified 11 olaparib treatmentspecific BRCA1 BRCT interactors, which are involved in various biological processes, such as cell cycle and transcription regulation.
The enrichment analysis revealed that the BRCT domains of BRCA1 interacts with proteins involved in canonical pathways such as DNA damage response, hereditary breast cancer and oestrogen signalling, or assembly of the RNA polymerase II Complex. Such results are in line with previously known roles of BRCA1 BRCT in the maintenance of genome integrity, regulation of cell cycle checkpoint and gene expression (29) . Interestingly, the canonical pathway "Role of BRCA1 in DNA Damage Response" was downregulated upon olaparib treatment, in particular, most of the members of the BRCA1-A complex (including RAP80, BRCC3, Abraxas) showed decreased binding to BRCA1 BRCT in response to olaparib (Supplementary Material, Table S3 ). Decreased binding of RAP80 is in agreement with previously described interaction of the protein complex PARP1-BRCA1-RAP80 which is dependent on PARP1-mediated PARsylation of BRCA1, which is inhibited upon olaparib treatment (34, 35) . Since the BRCA1-A complex plays a crucial role in DNA damage response by recognition of ubiquitinated H2AX and recruiting BRCA1 into the DNA damage site (36, 37) , olaparib treatment might thus partially affect this BRCA1-mediated function.
In addition, olaparib treatment induced phosphorylation of BRCA1 on the threonine residue at position 1834, which is located at the very end of the C-terminal BRCT domain. Phosphorylation of more than 100 distinct sites have been identified in BRCA1 up to date, however, their involvement in various cellular processes is elucidated only for some of them (38) . Output from the kinase prediction software GPS3.0 indicates the pro-apoptotic mixed lineage kinase 3 (MLK3) (39) as the most likely for this olaparib-induced BRCA1 phosphorylation.
When examining factors that could influence the cellular response to olaparib, we observed a slightly elevated, although not significant, PARP activity in cells harbouring c.5117G > A and c.5123C > A pathogenic missense variants in comparison to cells with truncating variants, indicating differences between these BRCA1 mutation types that might partially modulate their response to PARP inhibition ( Fig. 4A and B) . Indeed, the correlation between basal PARP enzymatic activity and sensitivity of cells to olaparib (Fig. 4C) indicates that it is, at least partially, dependent on the ability of PARP to play its enzymatic role. Previous research shows that hyperactivation of PARP1 is associated with an increased sensitivity of cells to PARP inhibitors, The differences between groups were evaluated using Mann-Whitney U test. caused by a homologous recombination-defective phenotype (40) .
To further explore the correlation between cellular sensitivity to olaparib and PARP enzymatic activity we investigated their connection to BRCA1-mediated DNA repair. Following on the exploration of the dominant-negative effect of our missense variants to explain their higher sensitivity to olaparib we tested a model that involves previously described two-phase BRCA1 recruitment to the DNA DSBs (22, 41) . Based on the research carried on by Li et al., WT BRCA1 heterodimerizes with BARD1 through its RING domain and is recruited into DSB ends by the interaction of BARD1 with PAR polymers within a minute post damage (early recruitment) (Fig. 6A) . The late recruitment of BRCA1 into cH2AX foci, phosphorylated H2AX playing a critical role in downstream signalling after the formation of DSBs and in retention of repair factors in the site of damaged DNA (42), takes part within minutes after damage. It requires functional BRCA1 BRCT domains and is dependent on a direct interaction with p-Abraxas, a member of the BRCA1-A complex subunit.
We propose that olaparib-induced inhibition of the early recruitment of BRCA1 into DSBs by preventing PAR polymerization makes cells more dependent on the late recruitment phase (Fig. 6C) . Moreover, olaparib-induced decrease in the BRCA1-A complex and BRCT interaction, shown by mass spectrometry, might make the cells rely on the remaining functions of the late recruitment stage even more. Cells harbouring heterozygous truncating mutation in the BRCA1 gene frequently lack the mutated protein due to the degradation of a mutated transcript by the nonsense-mediated mRNA decay mechanism (15, 43) . But the remaining WT protein would be able to function in the DSB repair through the late recruitment phase, which is consistent with the observed reduced BRCA1 recruitment when compared to WTs. On the other hand, cells carrying the two studied heterozygous missense mutations contain both functional (WT) and defective (mutant) BRCA1, as indicated by the comparable range of total BRCA1 protein levels in WT cells and cells carrying the studied missense variants (15) and detectable, therefore stable, mutants overexpressed in our TA assays. Thus, the WT and mutant protein could compete to undergo the late recruitment path to repair DNA DSBs (Fig. 6B and D) .
Indeed, confocal microscopy revealed decreased BRCA1 recruitment into cH2AX foci in non-treated cells carrying c.5117G > A and c.5123C > A missense variants when compared to WTs or cells with truncating mutations (Fig. 5A ), supporting our hypothesis about dominant-negative effect of the missense mutant. Although the exact mechanism of the reduced recruitment remains to be elucidated, it is likely that the nonfunctional mutant protein competes with WT BRCA1 for the BRCA1-A complex, required for an efficient late recruitment into DSBs. The observed correlation between BRCA1 recruitment into DSBs and cellular viability of olaparib-treated cells further supports our model. Together with the results from Bouwman et al, who showed a defect in response to olaparib in BRCT-located mutants R1699Q and V1736A (44) , it seems that the integrity of the BRCA1 BRCT domain plays a critical role in sensitivity to this agent. Systematic evaluation of other pathogenic variants in the BRCT, e.g. c.5095C > T; p.Arg1699Trp which is shown to lead to a stable mutant protein (30) , will be required in order to assess the ability of these mutants to act in a dominant-negative manner. Interestingly, two recent studies elucidate a new mechanism of acquired resistance to PARP inhibitor or cisplatin due to a residual function of RING-less BRCA1 protein (45, 46) . Thus, missense pathogenic variants in the N-terminal RING domain could potentially also lead to PARPi resistance and caution should be taken when studying missense pathogenic variants located in different BRCA1 domains.
Overall, our results suggest that carriers of different types of BRCA1 mutations could show different toxicity to PARP inhibitor olaparib and could benefit from the treatment in a distinct way. Our findings could be also relevant for a potential use of PARP inhibitors as prophylactic agents in BRCA1 mutation carriers (47) . Importantly, although all missense variants represent 8.3% of BRCA1 mutations and missense mutations in the BRCT domain account for only 2% (14) , our results could be particularly important for Spanish population where c.5117G > A, p.Gly1706Glu and c.5123C > A, p.Ala1708Glu together represent close to 15% of all mutations found in BRCA1 (48). Thus, clearly, further research on differences between BRCA1 mutation types and the biology behind PARP inhibition could be of a great importance, particularly in this population.
Materials and Methods
Lymphoblastoid cell lines (LCLs)
LCLs were established by EBV-transformation of peripheral blood lymphocytes from fifteen women carrying heterozygous pathogenic variants in BRCA1 (BRCA1þ/-) and six non-carrier relatives (BRCA1þ/þ) (Table 2), as previously described (15) . Five LCLs carried one of the two missense pathogenic variants located in the BRCT domain of BRCA1 (c.5117G > A; p.Gly1706Glu or c.5123C > A; p.Ala1708Glu) and ten LCLs carried variants generating a premature stop codon (frameshift, nonsense or splicesite). Mutational analysis has been previously performed by Sanger sequencing. None of the women included in this study had personal antecedents of cancer.
Tissue culture and treatments
LCLs were cultured in RPMI-1640 (Sigma-Aldrich) supplemented with 20% FBS (Sigma-Aldrich), penicillin-streptomycin (Gibco) and Fungizone (Gibco). Cells were cultured in 25 cm 2 flasks (Corning) and maintained in exponential growth by daily dilution to 1x10 6 cells/ml in full media. Early passages (1-10) were used for all experiments. HEK293FT cells were grown in DMEM media (Sigma-Aldrich) complemented with 10% FBS, 1% penicillin-streptomycin, and 0.5% Fungizone.
Where noted, cells were incubated with PARP inhibitor Olaparib (Axon Medchem) or its dissolvent DMSO (Sigma) (control) for indicated period of time. All cells were maintained in an atmosphere of 5% CO 2 at 37 C.
MTT colorimetric assay
200ul of cellular suspension was plated in 96-well plate at a density of 10 4 cells/well. Cells were then treated with DMSO or olaparib for 72 h under standard growth conditions. As LCLs tend to form large cellular aggregates, they were resuspended daily by pipetting up and down in order to ensure equal distribution of the treatment to all cells. 3 days after the beginning of treatment, 50ml of MTT dissolved in PBS (stock 5mg/ml MTT) was added onto a plate and incubated under normal growth conditions for 4 h. 50ml of SDS/HCl solution (500ml SDS 10% þ 150mL HCl 37%) was transferred into each well, and the plates were incubated in a tissue culture incubator for 16 h. Absorbance at 544 nm was read on a spectrophotometer (Victor 3 Plate Reader; PerkinElmer), data were normalized to a mean absorbance detected in wells containing media without cells (blank), and the results were expressed as a percentage of DMSO-treated cells.
Basal PARP enzymatic activity
The PARP enzymatic activity was determined using the HT Chemiluminescent PARP/Apoptosis Assay kit (Trevigen; #4685-096-K) according to the manufacturer's instructions with several modifications. 8x10 6 cells were washed once with ice-cold PBS and lyzed in 100 ll of Trevigen Cell Extraction Buffer (1x I-PAR Assay buffer; 0.4 mol/L NaCl, 0.9% Triton X-100, Complete protease inhibitor cocktail [Roche]) on ice for 30 min and periodically vortexed. After centrifugation of the cellular lysates at 10,000Âg at 4 C for 10 min, protein concentration was quantified using DC Protein Assay Kit II (Bio-Rad) using BSA as a standard. The cellular lysate (10 lg/well) was added in duplicates to the wells of 96-well plate, which contained PARP buffer and PARP cocktail, and incubated at room temperature for 1 h. Activated DNA was added only to the standards but not to extracts, which allowed to measure the basal enzymatic activity. Wells were washed with PBS and 0.1% Triton X-100 (PBS-T) and incubated with streptavidin horseradish peroxidase for 1 h and washed again. Chemiluminescent detection was performed according to the manufacturer's instructions (EnVision Multilabel Plate Reader; PerkinElmer). The background luminescence (blank) was subtracted from the readings of the samples and standards served for calculation of PARP activity from a standard curve.
Cellular growth rate calculation
Differences in the cellular growth rate were determined using the above mentioned MTT colorimetric assay with some modifications. From each LCL 10 4 cells/well/200ul full media were plated in hexaplicates into two separate 96-well plates. The first plate was subjected to an MTT addition at time 0 h whereas the MTT solution was added into the second plate 72 h later, i.e. the same duration as for determination of sensitivity to PARP inhibitors was used to determine the growth rate of LCLs. Plates were incubated with the MTT for 4 h which was followed by incubation with SDS/HCl solution for additional 16 h. Absorbance at 544 nm was measured on a spectrophotometer and the data were normalized to a mean absorbance detected in wells containing media without cells. The growth rate was calculated as a ratio between the mean absorbance from 72-h timepoint and the mean absorbance at 0 h.
RNA extraction and quantification
RNA was extracted using TRIzol Reagent (Invitrogen) according to the manufacture rs instructions. RNA quality and quantity was determined using LabChip technology on Agilent 2100 BioAnalyser (Agilent Technologies) with the value of RNA integrity number (RIN) between 9.9 and 10.0.
Quantitative real-time RT-PCR 500ng of total RNA was reverse-transcribed by High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacture rs instructions. Using labelled probes (Roche Universal ProbeLibrary) and TaqMan Universal PCR Mix the cDNAs were analysed by quantitative RT-PCR assay in an ABI Prism Sequence Detection System 7900HT (Applied Biosystems). F-primer 5-CTGGAGGACGACAAGGAAAA-3' and R-primer 5-TGTTGCTACCGATCACCGTA-3' were used in the quantitative RT-PCR for detection of PARP1 expression. Expression levels of HPRT1 and MRLP19 were used as internal controls and enabled normalization of the samples. Three independent experiments were performed and the relative expression was calculated using a comparative Ct method.
Western blot analysis
For PARP1 and PAR protein detection, whole cell lysates were prepared. Shortly, exponentially growing LCLs were harvested by centrifugation, washed twice with ice cold PBS and lysed in RIPA buffer (Sigma-Aldrich) containing protease inhibitor (Roche) for 1 h on ice. Lysates were centrifuged at 16,000 g for 20 min at 4 C and supernatants were transferred into new tubes for further protein quantification using Bio-Rad protein assay kit. 75lg of proteins from whole cell lysate was loaded per well of 4-12% Bis-Tris gel (Invitrogen). Separated proteins were transferred to a nitrocellulose membrane (Whatman) using the NuPage transfer system (Invitrogen) and the membrane was then blocked in Tris buffered saline containing 0.05% Tween-20 (TBS-T) and 5% milk. Blots were probed with following primary antibodies: rabbit anti-PARP1 (Cell Signaling; #9542), rabbit anti-PAR (Calbiochem; #528815), rabbit anti-RAD51 (Santa Cruz; #sc-8349), rabbit anti-GAL4-DBD (Santa Cruz; #sc-577). Mouse anti-b-actin (Sigma; #A5441) served as loading control. The secondary antibodies were HRP-conjugated (Dako) and the immunoblots were developed using the ECL system (GE Healthcare). Western blot X-ray films (Kodak) were scanned and analysed using ImageJ software. To mimic the heterozygous status, co-transfection of WT BRCA1 and pFLAG-CMV3 vector containing the BRCA1 A1708E variant (exons [16] [17] [18] [19] [20] [21] [22] [23] [24] and lacking the GAL4 DNA binding domain (GAL4-DBD) was performed. The vectors containing the variants were co-transfected with pG5Luc, which contains a firefly luciferase reporter gene driven by GAL4-responsive binding sites, and phGR-TK, which contains a Renilla luciferase gene driven by a constitutive TK basal promoter used as an internal control. 24 h post-transfection, growth medium was replaced by a medium containing either DMSO or 16lM OLP. Cells were harvested 24 h after the treatment, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega) following the manufacturer's instructions. Activity was plotted as a percentage of the WT BRCA1 activity of DMSOtreated cells.
BRCA1 transcriptional activation assay
Mass spectrometry
DMSO-or 16lM OLP-treated HEK293FT cells overexpressing pNTAP-BRCA1-BRCT construct were collected, lysed and proteins were extracted. Previously described protocol was used (Woods et al, 2012) to perform the mass spectrometry experiment. Briefly, protein fractions created by SDS-PAGE were excised, destained, reduced, alkylated and digested with trypsin (Promega). Peptides were eluted from the gel and concentrated using vacuum centrifugation. A nanoflow liquid chromatograph (U3000, Dionex, Sunnyvale, CA) coupled to an electrospray ion trap mass spectrometer (LTQ or LTQ-Orbitrap, Thermo, San Jose, CA) was used for tandem mass spectrometry peptide sequencing. Raw files were searched against the SwissProt human database (release year 2014) using a search engine Mascot (Matrix Science) (Perkins et al. 1999). The assignments were manually verified by inspection of the tandem mass spectra and coalesced into Scaffold reports (v.2.0, available at www.pro teomesoftware.com) for statistical analysis and data presentation. The Scaffold software was used to validate MS-MS based peptide and protein identifications. After applying the SAINT (Significance Analysis of INTeractome) algorithm and setting a probability threshold of 0.8 À 1, a final list of 121 protein interactors was selected.
BRCA1 recruitment into DNA double-strand breaks (DSBs)
Twelve DMSO-(control) and 10lM OLP-treated LCLs were seeded into poly-L-lysine-coated (Sigma-Aldrich) mCLEAR bottom 96-well plate (Greiner Bio-One) at a density 75000 cells/ 100ul full media/well and cultured 2 h before fixation with 4% paraformaldehyde (Aname). Cells were then permeabilised with 0.5% Triton X-100 in PBS and stained with primary and secondary antibodies: rabbit anti-cH2AX (Abcam; #ab11174), mouse anti-BRCA1 (Calbiochem; #OP92), anti-mouse Alexa Fluor 488-and anti-rabbit Alexa Fluor 568-conjugated secondary antibodies from Molecular Probes (Invitrogen; #A-11034 and #A-11031, respectively). 4 0 ,6-Diamidino-2-phenylindole dihydrochloride (DAPI) was used to visualize nuclei. Fluorescent images were automatically acquired from each well of the 96-well plate using an Opera High-Content Screening System (Perkin Elmer).
Pictures were taken at no saturating conditions using a 40x magnification lens and the intensity of BRCA1 fluorescent signal within detected cH2AX nuclear foci was evaluated for each LCL.
Only cells with at least 1 cH2AX nuclear foci were analysed and 1500 cells/LCL (merge of two duplicates) were included in the analysis.
Statistical analyses
To test the statistical difference between groups of LCLs independent samples Students t-test was used for normally distributed variables and Mann-Whitney U test for non-normal data distribution. Calculations were done using SPSS Statistics software (version 17.0; IBM) and plots were created with GraphPad Prism (version 5.03; GraphPad Software (www.graphpad.com) and Microsoft Office Excel, Microsoft).
Supplementary Material
Supplementary Material is available at HMG online.
